LAMEA Bronchodilators Market Size, Share & Industry Trends Analysis Report By Drug Class, By Route of Administration, By Disease (Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others), By Country and Growth Forecast, 2022

List of Tables

The Latin America, Middle East and Africa Bronchodilators Market would witness market growth of 7.8% CAGR during the forecast period (2022-2028).

One of the significant parameters responsible for the growth of the bronchodilator market is the decreasing functionality of lungs along with aging. These physical and cognitive changes generally make normal breathing difficult in the elderly. Also, the old adult population is more vulnerable to respiratory disorders like chronic obstructive pulmonary disease (COPD) and asthma.

The rising prevalence of respiratory diseases and the increased levels of air pollution, coupled with the surge in tobacco smokers, are boosting the incidence of infectious diseases among the elderly population, which significantly contribute toward the risk of developing lung disorders and collectively drive the growth of the market.

Anticholinergics are bronchodilators primarily utilized for treating COPD (chronic obstructive pulmonary disease, like emphysema) and asthma. Atrovent treats COPD and can be utilized off-label to treat asthma flares. Patients can get it as a nebulizer solution and inhaler. Revefenacin (Yupelri) is the new medication used regularly to aid those with COPD to breathe easier. Long-acting is taken once a day with a nebulizer.

In Saudi Arabia, the prevalence of the chronic obstructive pulmonary disease is 4.2% among the general population and 14.2% among smokers. In 2014, respiratory disease combined represented the fifth leading cause of death in Saudi Arabia, according to the Ministry of Health (MoH). Around 3388 people with respiratory diseases died in 2014 compared to 1892 in 2010. The rising prevalence of non-communicable diseases or chronic obstructive pulmonary disease will increase the need for medications like bronchodilators, thus, surging the market expansion in the region.

The Brazil market dominated the LAMEA Bronchodilators Market by Country in 2021; thereby, achieving a market value of $388.7 million by 2028. The Argentina market is showcasing a CAGR of 8.4% during (2022 - 2028). Additionally, The UAE market would register a CAGR of 7.5% during (2022 - 2028).

Based on Drug Class, the market is segmented into Beta-Adrenergic, Xanthine Derivatives, and Anticholinergic. Based on Route of Administration, the market is segmented into Nasal (Inhalable), Oral, and Injectable. Based on Disease, the market is segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glenmark Pharmaceuticals Limited, Merck & Co., Inc., GlaxoSmithKline PLC, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Cipla Limited, Viatris, Inc., Novartis AG, Boehringer Ingelheim International GmbH and Sun Pharmaceutical Industries Ltd.

Scope of the Study

Market Segments covered in the Report:

By Drug Class

Beta-Adrenergic
Xanthine Derivatives
Anticholinergic

By Route of Administration

Nasal (Inhalable)
Oral
Injectable

By Disease

Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Others

By Country

Brazil
Argentina
UAE
Saudi Arabia
South Africa
Nigeria
Rest of LAMEA

Companies Profiled

Glenmark Pharmaceuticals Limited
Merck & Co., Inc.
GlaxoSmithKline PLC
AstraZeneca PLC
Teva Pharmaceuticals Industries Ltd.
Cipla Limited
Viatris, Inc.
Novartis AG
Boehringer Ingelheim International GmbH
Sun Pharmaceutical Industries Ltd.

Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 LAMEA Bronchodilators Market, by Drug Class
- 1.4.2 LAMEA Bronchodilators Market, by Route of Administration
- 1.4.3 LAMEA Bronchodilators Market, by Disease
- 1.4.4 LAMEA Bronchodilators Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview

2.1 Introduction
- 2.1.1 Overview
  - 2.1.1.1 Market composition and Scenario
2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints

Chapter 3. LAMEA Bronchodilators Market by Drug Class

3.1 LAMEA Beta-Adrenergic Market by Country
3.2 LAMEA Xanthine Derivatives Market by Country
3.3 LAMEA Anticholinergic Market by Country

Chapter 4. LAMEA Bronchodilators Market by Route of Administration

4.1 LAMEA Nasal (Inhalable) Market by Country
4.2 LAMEA Oral Market by Country
4.3 LAMEA Injectable Market by Country

Chapter 5. LAMEA Bronchodilators Market by Disease

5.1 LAMEA Asthma Market by Country
5.2 LAMEA Chronic Obstructive Pulmonary Disease (COPD) Market by Country
5.3 LAMEA Others Market by Country

Chapter 6. LAMEA Bronchodilators Market by Country

6.1 Brazil Bronchodilators Market
- 6.1.1 Brazil Bronchodilators Market by Drug Class
- 6.1.2 Brazil Bronchodilators Market by Route of Administration
- 6.1.3 Brazil Bronchodilators Market by Disease
6.2 Argentina Bronchodilators Market
- 6.2.1 Argentina Bronchodilators Market by Drug Class
- 6.2.2 Argentina Bronchodilators Market by Route of Administration
- 6.2.3 Argentina Bronchodilators Market by Disease
6.3 UAE Bronchodilators Market
- 6.3.1 UAE Bronchodilators Market by Drug Class
- 6.3.2 UAE Bronchodilators Market by Route of Administration
- 6.3.3 UAE Bronchodilators Market by Disease
6.4 Saudi Arabia Bronchodilators Market
- 6.4.1 Saudi Arabia Bronchodilators Market by Drug Class
- 6.4.2 Saudi Arabia Bronchodilators Market by Route of Administration
- 6.4.3 Saudi Arabia Bronchodilators Market by Disease
6.5 South Africa Bronchodilators Market
- 6.5.1 South Africa Bronchodilators Market by Drug Class
- 6.5.2 South Africa Bronchodilators Market by Route of Administration
- 6.5.3 South Africa Bronchodilators Market by Disease
6.6 Nigeria Bronchodilators Market
- 6.6.1 Nigeria Bronchodilators Market by Drug Class
- 6.6.2 Nigeria Bronchodilators Market by Route of Administration
- 6.6.3 Nigeria Bronchodilators Market by Disease
6.7 Rest of LAMEA Bronchodilators Market
- 6.7.1 Rest of LAMEA Bronchodilators Market by Drug Class
- 6.7.2 Rest of LAMEA Bronchodilators Market by Route of Administration
- 6.7.3 Rest of LAMEA Bronchodilators Market by Disease

Chapter 7. Company Profiles

7.1 Glenmark Pharmaceuticals Limited
- 7.1.1 Company Overview
- 7.1.2 Financial Analysis
- 7.1.3 Research & Development Expenses
- 7.1.4 Recent strategies and developments:
  - 7.1.4.1 Product Launches and Product Expansions:
7.2 Merck & Co., Inc.
- 7.2.1 Company Overview
- 7.2.2 Financial Analysis
- 7.2.3 Segmental and Regional Analysis
- 7.2.4 Research & Development Expenses
7.3 GlaxoSmithKline PLC
- 7.3.1 Company Overview
- 7.3.2 Financial Analysis
- 7.3.3 Segmental and Regional Analysis
- 7.3.4 Research & Development Expense
7.4 AstraZeneca PLC
- 7.4.1 Company Overview
- 7.4.2 Financial Analysis
- 7.4.3 Regional Analysis
- 7.4.4 Research & Development Expenses
7.5 Teva Pharmaceutical Industries Ltd.
- 7.5.1 Company Overview
- 7.5.2 Financial Analysis
- 7.5.3 Regional Analysis
- 7.5.4 Research & Development Expenses
7.6 Cipla Limited
- 7.6.1 Company Overview
- 7.6.2 Financial Analysis
- 7.6.3 Regional Analysis
- 7.6.4 Research & Development Expense
7.7 Viatris, Inc. (Mylan N.V.)
- 7.7.1 Company Overview
- 7.7.2 Financial Analysis
- 7.7.3 Segmental and Regional Analysis
- 7.7.4 Research & Development Expense
7.8 Novartis AG
- 7.8.1 Company Overview
- 7.8.2 Financial Analysis
- 7.8.3 Segmental and Regional Analysis
- 7.8.4 Research & Development Expense
7.9 Boehringer Ingelheim International Gmbh
- 7.9.1 Company Overview
- 7.9.2 Financial Analysis
- 7.9.3 Regional & Segmental Analysis
- 7.9.4 Research & Development Expenses
7.10. Sun Pharmaceutical Industries Ltd.
- 7.10.1 Company Overview
- 7.10.2 Financial Analysis
- 7.10.3 Regional & Segmental Analysis
- 7.10.4 Research & Development Expenses

LIST OF TABLES

TABLE 1 LAMEA Bronchodilators Market, 2018 - 2021, USD Million
TABLE 2 LAMEA Bronchodilators Market, 2022 - 2028, USD Million
TABLE 3 LAMEA Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
TABLE 4 LAMEA Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
TABLE 5 LAMEA Beta-Adrenergic Market by Country, 2018 - 2021, USD Million
TABLE 6 LAMEA Beta-Adrenergic Market by Country, 2022 - 2028, USD Million
TABLE 7 LAMEA Xanthine Derivatives Market by Country, 2018 - 2021, USD Million
TABLE 8 LAMEA Xanthine Derivatives Market by Country, 2022 - 2028, USD Million
TABLE 9 LAMEA Anticholinergic Market by Country, 2018 - 2021, USD Million
TABLE 10 LAMEA Anticholinergic Market by Country, 2022 - 2028, USD Million
TABLE 11 LAMEA Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
TABLE 12 LAMEA Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
TABLE 13 LAMEA Nasal (Inhalable) Market by Country, 2018 - 2021, USD Million
TABLE 14 LAMEA Nasal (Inhalable) Market by Country, 2022 - 2028, USD Million
TABLE 15 LAMEA Oral Market by Country, 2018 - 2021, USD Million
TABLE 16 LAMEA Oral Market by Country, 2022 - 2028, USD Million
TABLE 17 LAMEA Injectable Market by Country, 2018 - 2021, USD Million
TABLE 18 LAMEA Injectable Market by Country, 2022 - 2028, USD Million
TABLE 19 LAMEA Bronchodilators Market by Disease, 2018 - 2021, USD Million
TABLE 20 LAMEA Bronchodilators Market by Disease, 2022 - 2028, USD Million
TABLE 21 LAMEA Asthma Market by Country, 2018 - 2021, USD Million
TABLE 22 LAMEA Asthma Market by Country, 2022 - 2028, USD Million
TABLE 23 LAMEA Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2018 - 2021, USD Million
TABLE 24 LAMEA Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2022 - 2028, USD Million
TABLE 25 LAMEA Others Market by Country, 2018 - 2021, USD Million
TABLE 26 LAMEA Others Market by Country, 2022 - 2028, USD Million
TABLE 27 LAMEA Bronchodilators Market by Country, 2018 - 2021, USD Million
TABLE 28 LAMEA Bronchodilators Market by Country, 2022 - 2028, USD Million
TABLE 29 Brazil Bronchodilators Market, 2018 - 2021, USD Million
TABLE 30 Brazil Bronchodilators Market, 2022 - 2028, USD Million
TABLE 31 Brazil Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
TABLE 32 Brazil Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
TABLE 33 Brazil Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
TABLE 34 Brazil Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
TABLE 35 Brazil Bronchodilators Market by Disease, 2018 - 2021, USD Million
TABLE 36 Brazil Bronchodilators Market by Disease, 2022 - 2028, USD Million
TABLE 37 Argentina Bronchodilators Market, 2018 - 2021, USD Million
TABLE 38 Argentina Bronchodilators Market, 2022 - 2028, USD Million
TABLE 39 Argentina Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
TABLE 40 Argentina Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
TABLE 41 Argentina Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
TABLE 42 Argentina Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
TABLE 43 Argentina Bronchodilators Market by Disease, 2018 - 2021, USD Million
TABLE 44 Argentina Bronchodilators Market by Disease, 2022 - 2028, USD Million
TABLE 45 UAE Bronchodilators Market, 2018 - 2021, USD Million
TABLE 46 UAE Bronchodilators Market, 2022 - 2028, USD Million
TABLE 47 UAE Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
TABLE 48 UAE Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
TABLE 49 UAE Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
TABLE 50 UAE Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
TABLE 51 UAE Bronchodilators Market by Disease, 2018 - 2021, USD Million
TABLE 52 UAE Bronchodilators Market by Disease, 2022 - 2028, USD Million
TABLE 53 Saudi Arabia Bronchodilators Market, 2018 - 2021, USD Million
TABLE 54 Saudi Arabia Bronchodilators Market, 2022 - 2028, USD Million
TABLE 55 Saudi Arabia Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
TABLE 56 Saudi Arabia Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
TABLE 57 Saudi Arabia Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
TABLE 58 Saudi Arabia Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
TABLE 59 Saudi Arabia Bronchodilators Market by Disease, 2018 - 2021, USD Million
TABLE 60 Saudi Arabia Bronchodilators Market by Disease, 2022 - 2028, USD Million
TABLE 61 South Africa Bronchodilators Market, 2018 - 2021, USD Million
TABLE 62 South Africa Bronchodilators Market, 2022 - 2028, USD Million
TABLE 63 South Africa Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
TABLE 64 South Africa Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
TABLE 65 South Africa Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
TABLE 66 South Africa Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
TABLE 67 South Africa Bronchodilators Market by Disease, 2018 - 2021, USD Million
TABLE 68 South Africa Bronchodilators Market by Disease, 2022 - 2028, USD Million
TABLE 69 Nigeria Bronchodilators Market, 2018 - 2021, USD Million
TABLE 70 Nigeria Bronchodilators Market, 2022 - 2028, USD Million
TABLE 71 Nigeria Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
TABLE 72 Nigeria Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
TABLE 73 Nigeria Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
TABLE 74 Nigeria Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
TABLE 75 Nigeria Bronchodilators Market by Disease, 2018 - 2021, USD Million
TABLE 76 Nigeria Bronchodilators Market by Disease, 2022 - 2028, USD Million
TABLE 77 Rest of LAMEA Bronchodilators Market, 2018 - 2021, USD Million
TABLE 78 Rest of LAMEA Bronchodilators Market, 2022 - 2028, USD Million
TABLE 79 Rest of LAMEA Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
TABLE 80 Rest of LAMEA Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
TABLE 81 Rest of LAMEA Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
TABLE 82 Rest of LAMEA Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
TABLE 83 Rest of LAMEA Bronchodilators Market by Disease, 2018 - 2021, USD Million
TABLE 84 Rest of LAMEA Bronchodilators Market by Disease, 2022 - 2028, USD Million
TABLE 85 Key Information - Glenmark Pharmaceuticals Limited
TABLE 86 KEY INFORMATION - Merck & Co., Inc.
TABLE 87 Key Information - GlaxoSmithKline PLC
TABLE 88 KEY INFORMATION - AstraZeneca PLC
TABLE 89 Key Information - Teva Pharmaceuticals Industries Ltd.
TABLE 90 Key Information - Cipla Limited
TABLE 91 key information - Viatris, Inc.
TABLE 92 Key Information - Novartis AG
TABLE 93 Key Information - Boehringer Ingelheim International GmbH
TABLE 94 Key Information - Sun Pharmaceutical Industries Ltd.

List of Figures

FIG 1 Methodology for the research

LAMEA Bronchodilators Market Size, Share & Industry Trends Analysis Report By Drug Class, By Route of Administration, By Disease (Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others), By Country and Growth Forecast, 2022 - 2028

Description

Table of Contents